How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Novo Nordisk, a Danish pharmaceutical company, developed Ozempic and related GLP-1 drugs for weight loss that generated significant revenue. Eli Lilly, a U.S. competitor, introduced its own GLP-1 drug and gained market share in the weight-loss medication sector. As of 2026, Eli Lilly's GLP-1 product held a larger share of the U.S. market for weight-loss drugs than Novo Nordisk's offering.

Next story